ADMA Biologics (ADMA) Tops Q3 EPS by 2c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $62.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Change in Nonfarm Payrolls (Aug) 162K vs 55K Expected, Unemployment Rate 4.1%
• CIENA (CIEN) PT Lowered to $394 at UBS on Group Multiple Compression